Hudson Bay Capital Management
UNCY icon

Hudson Bay Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Hudson Bay Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,484
Closed -$8.53K – 1655
2025
Q1 		$8.53K Buy
+1,484
New +$9.05K ﹤0.01% 1248

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hudson Bay Capital Management's UNCY Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of Unicycive Therapeutics (UNCY) in Q2 2025, closing a stake of 1,484 shares — an estimated $8.53K sold.

Hudson Bay Capital Management first reported a position in UNCY in Q1 2025 and held it in 1 quarter. The position peaked at $8.53K in Q1 2025. 20 funds tracked by Wall St. Rank hold UNCY as of Q2 2025.

  • Hudson Bay Capital Management reported no remaining Unicycive Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,484 Unicycive Therapeutics shares in Q2 2025, an estimated $8.53K.
  • Hudson Bay Capital Management first reported a position in Unicycive Therapeutics in Q1 2025 and held it in 1 quarter.
  • Hudson Bay Capital Management's Unicycive Therapeutics position peaked at $8.53K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.